HRMY Harmony Pharma: Accounting Value per Share

Harmony Biosciences (HRMY) - corporate logo

Harmony Biosciences (HRMY) is a biopharmaceutical player in the neurology sector whose success relies on its market share of narcolepsy treatments, patent purity, and new drug formulations. Business efficiency is based on Wakix prescription dynamics, the expansion of FDA approvals, and an operating margin that is currently 17.28. This daily price chart, provided for analytical convenience, allows for a real-time assessment of the asset while the R&D pipeline develops innovative molecules to combat CNS pathologies.

Harmony Biosciences Inc (HRMY) Equity per Share: for the period 07/04/2022 - 10/28/2026

harmonybiosciences.com - analytical breakdowns and key metrics (HRMY)

- price and consensus price forecast:
Price Chart Harmony Pharma|HRMY - Consensus Target
- market capitalization data:
Market Valuation Harmony Biosciences Holdings, Inc.|HRMY - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Harmony Biosciences|HRMY - Accounting Capitalization|Market Capitalization to Book Value Ratio harmonybiosciences.com|HRMY - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Harmony Biosciences|HRMY - Long-Term Debt to Capital|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc.|HRMY - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Harmony Biosciences Holdings, Inc.|HRMY - Long-Term Debt|Company Short-Term Debts Harmony Biosciences
Fundamental company valuation:Harmony Pharma, HRMY
Manufactured products of Harmony Biosciences Holdings, Inc.

Harmony Biosciences operates in the orphan drug segment for sleep disorders, possessing exceptional resilience to macroeconomic shocks. Net asset dynamics directly impact the book value per share, reflecting the difference between total equity and liabilities. This metric captures the actual tangible backing of each security by the issuer's balance sheet capital. It is critical for investors to compare this basis with the market price to identify unjustified premiums. Analysis based on the book value per share allows for an assessment of drawdown risk in the event of rising debt costs.

Competitors of Harmony Biosciences (HRMY)

BIIB: Net Assets per Single Share|Neurocrine Corp (NBIX) - Accounting Value per Share|Accounting Value per Share RGC|AXSM (axsome.com) - Net Asset Value per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Biohaven (BHVN)|AMLX: Accounting Value of a Share|Net Assets per Single Share TRVI|Praxis Corp (PRAX) - Net Asset Value per Share|AVXL - Book Value per Share|Accounting Value of a Share ceribell.com|Book Value per Share PRTA|Book Value per Share ALEC (alector.com)|Net Assets per Single Share Annexon Inc.|Omeros Corp - Accounting Value of a Share|NGNE: Net Assets per Single Share|ACIU: Accounting Value per Share|Net Assets per Single Share VYGR|NMRA (Neumora) - Net Asset Value per Share|Net Assets per Single Share Scilex Holding Co. (SCLX)|Equity per Share Tevogen Bio Inc. (TVGN)|Alpha Cognition - Accounting Value per Share|Net Asset Value per Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc.|Accounting Value of a Share Cassava Sciences Inc SAVA|ASRT - Book Value per Share|COYA - Net Assets per Single Share|vistagen.com - Book Value per Share|OVID (Ovid Therapeutics) - Net Assets per Share|Net Assets per Single Share ABOS (Acumen Pharmaceuticals, Inc.)|Net Asset Value per Share CRVO|ATHE (Alterity Therapeutics) - Net Assets per Single Share|Net Assets per Share clene.com (CLNN)|PepGen - Book Value per Share|Accounting Value per Share Jupiter Neurosciences, Inc. JUNS|Book Value per Share RLMD (Relmada Therapeutics, Inc.)|ANVS - Net Assets per Share|Book Value per Share GRCE|AIFF (Firefly Neuro) - Net Asset Value per Share|Net Assets per Single Share ANEW Medical (KLTO)|Equity per Share NeuroSense Therapeutics, Ltd.|Book Value per Share RVPH (Reviva Pharmaceuticals Holdings, Inc.)|Accounting Value per Share metaviatx.com (MTVA)|NRXS: Book Value per Share|Helius Medical Technologies, Inc. - Net Asset Value per Share|Net Assets per Single Share PASG (Passage Bio Corp)|NEUP - Net Assets per Share|Book Value per Share Minerva Neurosciences, Inc. NERV|ATHA (Athira Pharma Inc) - Accounting Value of a Share|ADXN - Net Assets per Single Share|Accounting Value of a Share ALZN|Net Assets per Single Share CYCN (Cyclerion Therapeutics)|Accounting Value per Share protagenic.com PTIX|KTTA: Accounting Value per Share|Cortigent Inc - Net Asset Value per Share|Avenue Therapeutics, Inc (ATXI) - Net Assets per Single Share|BCLI - Equity per Share|Book Value per Share CARA|Net Asset Value per Share chromocell.com|ELYM (Eliem Therapeutics, Inc.) - Accounting Value per Share|Book Value per Share ITCI|Longboard Pharma (LBPH) - Net Assets per Single Share|Accounting Value of a Share MRNS (Marinus Pharma)|NKGN: Net Assets per Single Share|Net Asset Value per Share neurobopharma.com NRBO|Book Value per Share Sage Therapeutics (SAGE)|SNPX - Accounting Value of a Share|TRVN: Book Value per Share|VIGL (Vigil Neuroscience, Inc.) - Book Value per Share|WENA - Net Assets per Single Share|Accounting Value of a Share CERE